Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

Table 3 Mixed models for percentage change of bone mineral density from baseline

Effect	Estimate	Standard error	P value
Hip
Treatment arm^a	0.042	0.022	0.069
Time	0.004	0.022	0.838
BMD value at baseline	-0.446	0.131	0.001
Lumbar spine
Treatment arm^{a, b}	0.018	0.027	0.506
Time^c	-0.035	0.022	0.122
Time × treatment arm^d	0.090	0.030	0.004
BMD value at baseline	-0.328	0.113	0.005

^aReference category is treatment arm A (A+R versus A). ^bTreatment arm effect at 12 months. ^cTime effect for arm A. ^dTreatment arm effect at 24 months. A, anastrozole; BMD, bone mineral density; R, risedronate.

ISSN: 1465-542X